OLMA

MKT CAP:$1B

Olema Pharmaceuticals, Inc.

Market Cap

$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$15.35-$9.93 (-39.28%)

Apr 23, 2026

Company Details

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagon...

CEO

Sean Bohen

IPO Date

Nov 19, 2020

Website

www.olema.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$162M

EPS (Diluted)

-$1.87

Free Cash Flow

-$147M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 16, 2026

$0EPS -$1.87

Q4 2025

Mar 16, 2026

$0EPS -$0.51

Q3 2025

Nov 10, 2025

$0EPS -$0.49

Q2 2025

Aug 11, 2025

$0EPS -$0.51

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$23M
Q2 22	$0	$0	-$33M
Q3 22	$0	$0	-$23M
Q4 22	$0	$0	-$27M
Q1 23	$0	$0	-$30M
Q2 23	$0	$0	-$22M
Q3 23	$0	$0	-$23M
Q4 23	$0	$0	-$30M
Q1 24	$0	$0	-$34M
Q2 24	$0	$0	-$34M
Q3 24	$0	$0	-$38M
Q4 24	$0	$0	-$37M
Q1 25	$0	$0	-$35M
Q2 25	$0	$0	-$48M
Q3 25	$0	$0	-$46M
Q4 25	$0	-$187.0K	-$50M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$18M	-$18M
Q2 22	-$26M	-$26M
Q3 22	-$18M	-$18M
Q4 22	-$20M	-$20M
Q1 23	-$20M	-$20M
Q2 23	-$22M	-$22M
Q3 23	-$23M	-$23M
Q4 23	-$18M	-$18M
Q1 24	-$23M	-$24M
Q2 24	-$28M	-$28M
Q3 24	-$27M	-$27M
Q4 24	-$26M	-$26M
Q1 25	-$44M	-$44M
Q2 25	-$30M	-$30M
Q3 25	-$35M	-$35M
Q4 25	-$38M	-$38M

Capital Expenditures

Quarter	CapEx
Q1 22	$30.0K
Q2 22	$21.0K
Q3 22	$139.0K
Q4 22	$173.0K
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$153.0K
Q2 24	$6.0K
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+50.5%
Q2 22	—	+101.5%
Q3 22	—	+30.7%
Q4 22	—	+25.1%
Q1 23	—	+27.3%
Q2 23	—	-35.1%
Q3 23	—	+0.5%
Q4 23	—	+11.7%
Q1 24	—	+16.0%
Q2 24	—	+55.2%
Q3 24	—	+61.2%
Q4 24	—	+20.9%
Q1 25	—	+1.6%
Q2 25	—	+42.7%
Q3 25	—	+21.9%
Q4 25	—	+36.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$5M	—
Q1 23	$0	—
Q2 23	$0	—
Q3 23	$4M	—
Q4 23	$4M	—
Q1 24	$5M	—
Q2 24	$6M	—
Q3 24	$6M	—
Q4 24	$6M	—
Q1 25	$4M	—
Q2 25	$5M	—
Q3 25	$4M	—
Q4 25	$4M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$16M	$7M
Q2 22	$27M	$6M
Q3 22	$18M	$6M
Q4 22	$22M	$6M
Q1 23	$23M	$7M
Q2 23	$18M	$4M
Q3 23	$19M	$4M
Q4 23	$26M	$5M
Q1 24	$30M	$4M
Q2 24	$29M	$4M
Q3 24	$33M	$4M
Q4 24	$32M	$4M
Q1 25	$31M	$4M
Q2 25	$44M	$4M
Q3 25	$40M	$6M
Q4 25	$43M	$7M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$22M	$246M	$268M
Q2 22	$25M	$216M	$241M
Q3 22	$27M	$196M	$223M
Q4 22	$24M	$181M	$204M
Q1 23	$41M	$145M	$186M
Q2 23	$35M	$132M	$167M
Q3 23	$117M	$159M	$277M
Q4 23	$69M	$193M	$262M
Q1 24	$34M	$215M	$249M
Q2 24	$17M	$222M	$239M
Q3 24	$36M	$179M	$215M
Q4 24	$139M	$295M	$434M
Q1 25	$51M	$342M	$393M
Q2 25	$52M	$309M	$362M
Q3 25	$35M	$294M	$329M
Q4 25	$48M	$457M	$505M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	40M	+0.2%	+1.3%
Q2 22	40M	+0.2%	+1.3%
Q3 22	40M	+0.3%	+1.1%
Q4 22	40M	+0.4%	+1.1%
Q1 23	40M	+0.4%	+1.3%
Q2 23	41M	+0.9%	+2.0%
Q3 23	45M	+10.5%	+12.3%
Q4 23	55M	+21.8%	+36.3%
Q1 24	56M	+1.4%	+37.7%
Q2 24	56M	+1.3%	+38.2%
Q3 24	57M	+1.7%	+27.3%
Q4 24	59M	+2.6%	+7.2%
Q1 25	85M	+45.4%	+53.7%
Q2 25	85M	+0.1%	+51.9%
Q3 25	86M	+0.3%	+49.7%
Q4 25	91M	+6.5%	+55.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	74
Q2 22	$0	74
Q3 22	$0	74
Q4 22	$0	86
Q1 23	$0	86
Q2 23	$0	86
Q3 23	$0	86
Q4 23	$0	74
Q1 24	$0	74
Q2 24	$0	74
Q3 24	$0	74
Q4 24	$0	96
Q1 25	$0	96
Q2 25	$0	96
Q3 25	$0	96
Q4 25	$0	10K

Revenue / Employee